论文部分内容阅读
目的:研究葛根素β-环糊精包合物与葛根素原料药口服灌胃后小鼠体内的生物利用度。方法:采用HPLC测定小鼠血中葛根素浓度,药-时曲线数据用DAS2.1.1版药动学分析软件处理。结果:葛根素在小鼠体内药动学过程符合二室模型,葛根素原料药的AUC、Cmax和Tmax分别为1657.28 mg.L-1.min-1、26.34 mg.L-1和30min,而葛根素β-环糊精包合物的AUC、Cmax和Tmax分别为3504.30 mg.L-1.min、77.34 mg.L-1和30 min,统计结果表明AUC之间有显著性差异。结论:葛根素进行β-环糊精包合后可以提高葛根素的口服生物利用度。
Objective: To study the bioavailability of puerarin β-cyclodextrin inclusion complex and puerarin bulk drug in mice after oral gavage. Methods: The concentration of puerarin in the blood of mice was determined by HPLC. The drug-time curve data was processed with the DAS 2.1.1 pharmacokinetic analysis software. RESULTS: The pharmacokinetics of puerarin in mice met the two-compartment model. The AUC, Cmax and Tmax of puerarin API were 1657.28 mg.L-1.min-1, 26.34 mg.L-1 and 30 min, respectively. The AUC, Cmax and Tmax of puerarin β-cyclodextrin inclusions were 3504.30 mg.L-1.min, 77.34 mg.L-1 and 30 min, respectively. The statistical results showed that there was a significant difference between AUC. CONCLUSION: Puerarin can enhance the oral bioavailability of puerarin after beta-cyclodextrin inclusion.